Skip to main content
. Author manuscript; available in PMC: 2011 Apr 12.
Published in final edited form as: Immunol Rev. 2010 Jan;233(1):126–145. doi: 10.1111/j.0105-2896.2009.00863.x

Table 1. U1-70K autoantibody epitopes.

Sequence Species Disease, % Reactivity, (N) Reference
52–77 Human MCTD, 53%, (17); SLE, 63%, (16); Scleroderma, 0% (6) (64)
63–84 Human RNP + SLE, 100%, (3) (160)
94–194 Human/mouse RNP+, 90%, (113)/MRL/lpr, 85% (7) (161)
100–156 Human MCTD, 94% (17); SLE, 81%, (16); Scleroderma, 83%, (6) (64)
119–126 Human RNP+, (25) (162)
124–372 Human RNP+ (SLE/MCTD), 100%, (17) (63)
131–151 Human/mouse SLE, 66%, (3)/MRL/lpr (67)
143–195 Human RNP+ CTD, 93%, (16) (66)
195–259 Human/mouse RNP+, 0.1%, (113)/MRL/lpr, 0.12%, (8) (161)
196–259 Human MCTD, 24%, (17); SLE, 94%, (16); Scleroderma, 50%, (6) (64)
217–234 Human RNP+ SLE, 66%, (3) (160)
234–253 Human RNP+, 10%, (180) (65)
276–297 Human RNP+ (SLE/MCTD), 90%, (17) (63)
276–371 Human RNP+, 100%, (180) (65)
282–296 Human RNP+ SLE, 90%, (10) (163)
386–437 Human MCTD, 35%, (17); SLE, 74%, (16); Scleroderma, 33%, (6) (64)

MCTD, mixed connective tissue disease; SLE, systemic lupus erythematosus; RNP, ribonuleoprotein.